Boehringer Ingelheim and Walgreens have joined forces to revolutionize clinical trials. Through this collaboration, people with obesity, overweight, and type 2 diabetes will have access to a Phase III clinical trial in a convenient setting – Walgreens pharmacies.
This initiative aims to remove obstacles, promote equity, and enhance the representation of diverse communities in clinical trials. Black and Hispanic adults, who are disproportionately affected by obesity, have historically been underrepresented.
Walgreens’ Chief Clinical Trials Officer, Ramita Tandon, emphasizes the significance of this collaboration in advancing community health and innovation. The model empowers individuals by providing education on clinical research and offering a novel avenue for active participation in their healthcare journey.
Boehringer Ingelheim’s partnership with EmVenio Research further extends the reach of this initiative. Mobile research units will bring clinical trials directly to local communities, providing additional options for participation.
Lennart Jungersten, Senior Vice President of Medicine and Regulatory Affairs at Boehringer Ingelheim U.S., indicated that they are making clinical trials more accessible, helping to provide access to diverse populations with pressing health needs when bringing clinical trials to the communities.
Obesity affects over 1 billion people worldwide, and projections indicate that by 2035, approximately 24% of the global population will be affected. By leveraging the expertise of pharmacies and mobile research units, this collaboration aims to transform the clinical research landscape, making it more inclusive and equitable while paving the way for transformative healthcare solutions for future generations.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
